Jinwon Life Sciences Applies for US FDA Phase 2 Clinical Approval of COVID-19 Infection Prevention Drug
[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 23rd that it has submitted an application for approval of a Phase 2 clinical trial using GLS-1200 to the U.S. Food and Drug Administration (FDA) targeting healthcare workers who are at significant risk of exposure to the novel coronavirus infection (COVID-19) to prevent infection in advance.
The company explained, "We applied after consulting in advance with the U.S. FDA on the drug repositioning strategy of applying GLS-1200 to prevent COVID-19 virus infection."
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Park Younggeun, CEO of GeneOne Life Science, said, "Our company is developing a nucleic acid vaccine to combat the COVID-19 infectious disease threatening the world," and emphasized, "To end COVID-19, it is necessary to develop drugs that prevent infection by the COVID-19 virus along with vaccine and therapeutic development."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
